Skip to main content
PMC home page
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 2004 Sep;81(3):453–471. doi: 10.1093/jurban/jth130

Cost-effectiveness of universal screening for chlamydia and gonorrhea in US jails

Julie R Kraut-Becher 1,2,✉, Thomas L Gift 3, Anne C Haddix 4, Kathleen L Irwin 3, Robert B Greifinger 4
PMCID: PMC3455948  PMID: 15273268

Abstract

Universal screening for the sexually transmitted diseases (STDs) of chlamydia and gonorrhea on intake in jails has been proposed as the most effective strategy to decrease morbidity in inmates and to reduce transmission risk in communities after release. Most inmates come from a population that is at elevated risk for STDs and has limited access to health care. However, limited resources and competing priorities force decision makers to consider the cost of screening programs in comparison to other needs. The costs and cost-effectiveness of universal screening in correctional settings have not been documented. We estimated the incremental cost-effectiveness of universal urine-based screening for chlamydia and gonorrhea among inmates on intake in US jails compared to the commonly used practice of presumptive treatment of symptomatic inmates without laboratory testing. Decision analysis models were developed to estimate the cost-effectiveness of screening alternatives and were applied to hypothetical cohorts of male and female inmates. For women, universal screening for chlamydia only was cost-saving to the health care system, averting more health care costs than were incurred in screening and treatment. However, for men universal chlamydia screening cost $4,856 more per case treated than presumptive treatment. Universal screening for both chlamydia and gonorrhea infection cost the health care system $3,690 more per case of pelvic inflammatory disease averted for women and $650 more per case of infection treated for men compared to universal screening for chlamydia only. Jails with a high prevalence of chlamydia and gonorrhea represent an operationally feasible and cost-effective setting to universally test and treat women at high risk for STDs and with limited access to care elsewhere.

Keywords: Chlamydia, Cost-effectiveness analysis, Gonorrhea, Jails, Screening

Full Text

The Full Text of this article is available as a PDF (160.4 KB).

References

  • 1.The Health Status of Soon-to-Be-Released Inmates: a Report to Congress. Chicago, IL: National Commission on Correctional Health Care; 2002. [Google Scholar]
  • 2.Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002;92:1789–1794. doi: 10.2105/ajph.92.11.1789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Mertz KJ, Schwebke JR, Gaydos CA, Beidinger HA, Tulloch SD, Levine WC. Screening women in jails for chlamydia and gonococcal infection using urine tests: Feasibility, acceptability, prevalence, and treatment rates. Sex Transm Dis. 2002;29:271–276. doi: 10.1097/00007435-200205000-00004. [DOI] [PubMed] [Google Scholar]
  • 4.Puisis M, Levine WC, Mertz KJ, et al. Overview of sexually transmitted diseases in correctional facilities. In: Puisis M, Anno BJ, Cohen RL, et al., editors. Clinical Practice in correctional Medicine. St. Louis, MO: Mosby; 1998. pp. 129–135. [Google Scholar]
  • 5.Holmes MD, Safyer SM, Bickell NA, Vermund SH, Hanff PA, Phillips RS. Chlamydial cervical infection in jailed women. Am J Public Health. 1993;83:551–555. doi: 10.2105/ajph.83.4.551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bickell NA, Vermund SH, Holmes MD, Safyer SM, Burk RD. Human papillomavirus, gonorrhea, syphilis, and cervical dysplasia in jailed women. Am J Public Health. 1991;81:1318–1320. doi: 10.2105/AJPH.81.10.1318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sexually Transmitted Disease Surveillance, 2000. Atlanta, GA: US Dept of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention; 2001. [Google Scholar]
  • 8.Glaser JB, Greifinger RB. Correctional health care: a public health opportunity. Ann Intern Med. 1993;118:139–145. doi: 10.7326/0003-4819-118-2-199301150-00010. [DOI] [PubMed] [Google Scholar]
  • 9.Glaser JB. Sexually transmitted diseases in the incarcerated. An underexploited public health opportunity [editorial] Sex Transm Dis. 1998;25:308–309. doi: 10.1097/00007435-199807000-00007. [DOI] [PubMed] [Google Scholar]
  • 10.Conklin TJ, Lincoln T, Tuthill RW. Self-reported health and prior health behaviors of newly admitted correctional inmates. Am J Public Health. 2000;90:1939–1941. doi: 10.2105/ajph.90.12.1939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.STD Services in Jails: an Opportunity to Improve the Health of the Larger Community. Results From the 1997 STD Correctional Health Assessment. Atlanta, GA: US Dept of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention; 1998. [Google Scholar]
  • 12.Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992;19:61–77. [PubMed] [Google Scholar]
  • 13.Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75:3–17. doi: 10.1136/sti.75.1.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Chesson HW, Pinkerton SD. Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immune Defic Syndr. 2000;24:48–56. doi: 10.1097/00126334-200005010-00009. [DOI] [PubMed] [Google Scholar]
  • 15.Standards for Health Services in Jails. Chicago, IL: National Commission on Correctional Health Care; 1996. [Google Scholar]
  • 16.Stamm WE. Toward control of sexually transmitted chlamydial infections. Ann Intern Med. 1993;119:432–434. doi: 10.7326/0003-4819-119-5-199309010-00017. [DOI] [PubMed] [Google Scholar]
  • 17.Eng TR, Butler WT, editors. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Washington, DC: National Academy Press; 1997. The neglected health and economic impact of STD; pp. 28–68. [Google Scholar]
  • 18.Marrazzo JM, White CL, Krekeler B, et al. Community-based urine screening for Chlamydia trachomatis with a ligase chain reaction assay. Ann Intern Med. 1997;127:796–803. doi: 10.7326/0003-4819-127-9-199711010-00004. [DOI] [PubMed] [Google Scholar]
  • 19.Oh MK, Smith KR, O'Cain M, Kilmer D, Johnson J, Hook EW. Urine-based screening of adolescents in detention to guide treatment for gonococcal and chlamydial infections. Arch Pediatr Adolesc Med. 1998;152:52–56. doi: 10.1001/archpedi.152.1.52. [DOI] [PubMed] [Google Scholar]
  • 20.Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: the case for screening. Prev Med. 2003;36:502–509. doi: 10.1016/S0091-7435(02)00058-0. [DOI] [PubMed] [Google Scholar]
  • 21.Kamb ML, Newman D, Peterman TA, et al. Most bacterial STD are asymptomatic [abstract]. Presented at: STIs at the Millennium Conference; May 3–7, 2000; Baltimore, MD.
  • 22.Mertz KJ, Voigt RA, Hutchins K, Levine WC, the Jail STD Prevalence Monitoring Group Findings from STD screening of adolescents and adults entering corrections facilities: implications for STD control strategies. Sex Transm Dis. 2002;29:834–839. doi: 10.1097/00007435-200212000-00016. [DOI] [PubMed] [Google Scholar]
  • 23.Parece MS, Herrera GA, Voigt RF, Middlekauff SL, Irwin KL. STD testing policies and practices in US city and county jails. Sex Transm Dis. 1999;26:431–437. doi: 10.1097/00007435-199909000-00003. [DOI] [PubMed] [Google Scholar]
  • 24.Cohen D, Scribner R, Clark J, Cory D. The potential role of custody facilities in controlling sexually transmitted diseases. Am J Public Health. 1992;82:552–556. doi: 10.2105/ajph.82.4.552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Beltrami JF, Cohen DA, Hamrick JT, Farley TA. Rapid screening and treatment for sexually transmitted diseases in arrestees: a feasible control measure. Am J Public Health. 1997;87:1423–1426. doi: 10.2105/ajph.87.9.1423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Centers for Disease Control and Prevention Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections—2002. MMWR Morb Mortal Wkly Rep. 2002;51(RR-15):1–40. [PubMed] [Google Scholar]
  • 27.Berger RE, et al. Acute epididymitis. In: Holmes KK, Sparling PF, Mardh P, et al., editors. Sexually Transmitted Diseases. New York: McGraw-Hill; 1999. pp. 847–858. [Google Scholar]
  • 28.Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996. [Google Scholar]
  • 29.Haddix AC, Teutsch SM, Corso PS, editors. Prevention Effectiveness: a Guide to Decision Analysis and Economic Evaluation. 2nd ed. New York: Oxford University Press; 2003. [Google Scholar]
  • 30.Hammett TM. Making the case for health interventions in correctional facilities. J Urban Health. 2001;78:236–240. doi: 10.1093/jurban/78.2.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Dicker LW, Mosure DJ, Berman SM, Levine WC. Regional Infertility Prevention Program. Gonorrhea prevalence and coinfection with chlamydia in women in the United States, 2000. Sex Transm Dis. 2003;30:472–476. doi: 10.1097/00007435-200305000-00016. [DOI] [PubMed] [Google Scholar]
  • 32.Washington AE, Johnson RE, Sanders LL. Chlamydia trachomatis infections in the United States. What are they costing us? JAMA. 1987;257:2070–2072. doi: 10.1001/jama.257.15.2070. [DOI] [PubMed] [Google Scholar]
  • 33.Haddix AC, Hillis SD, Kassler WJ. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis. 1995;22:274–280. doi: 10.1097/00007435-199509000-00002. [DOI] [PubMed] [Google Scholar]
  • 34.Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol. 2002;100:456–463. doi: 10.1016/S0029-7844(02)02118-X. [DOI] [PubMed] [Google Scholar]
  • 35.Douglas JM, Newman D, Bolan G, et al. Low rate of pelvic inflammatory disease (PID) among women with incident Chlamydia trachomatis (CT) infection. Int J STD AIDS. 2001;12(suppl 2):65–65. [Google Scholar]
  • 36.Magid D, Douglas JM, Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med. 1996;124:89–99. doi: 10.7326/0003-4819-124-4-199602150-00002. [DOI] [PubMed] [Google Scholar]
  • 37.Gift T, Owens C. The direct medical costs of epididymitis and orchitis: evidence from an analysis of insurance claims [abstract]. Presented at: ISSTDR Congress; July 28–30, 2003; Ottawa, Ontario, Canada.
  • 38.Rein D, Kassler W, Irwin K, Rabiee L. Direct medical cost of pelvic inflammatory disease and its sequelae: decreasing, but still substantial. Obstet Gynecol. 2000;95:397–402. doi: 10.1016/S0029-7844(99)00551-7. [DOI] [PubMed] [Google Scholar]
  • 39.Shafer MA, Pantell RH, Schachter J. Is the routine pelvic examination needed with the advent of urine-based screening for sexually transmitted diseases? Arch Pediatr Adolesc Med. 1999;153:119–125. doi: 10.1001/archpedi.153.2.119. [DOI] [PubMed] [Google Scholar]
  • 40.Hook EW, Handsfield HH, et al. Gonococcal infections in the adult. In: Holmes KK, Sparling PF, Mardh P, et al., editors. Sexually Transmitted Diseases. New York: McGraw-Hill; 1999. pp. 451–466. [Google Scholar]
  • 41.Stamm WE, et al. Chlamydia trachomatis infections of the adult. In: Holmes KK, Sparling PF, Mardh P, et al., editors. Sexually Transmitted Diseases. New York: McGraw-Hill; 1999. pp. 407–422. [Google Scholar]
  • 42.Risser JMH, Risser WL, Gefter LR, Brandstetter DM, Cromwell PF. Implementation of a screening program for chlamydial infection in incarcerated adolescents. Sex Transm Dis. 2001;28:43–44. doi: 10.1097/00007435-200101000-00010. [DOI] [PubMed] [Google Scholar]
  • 43.Oh MK, Cloud GA, Wallace LS, Reynolds J, Sturdevant M, Feinstein RA. Sexual behavior and sexually transmitted diseases among male adolescents in detention. Sex Transm Dis. 1994;21:127–132. doi: 10.1097/00007435-199405000-00001. [DOI] [PubMed] [Google Scholar]
  • 44.Pol B, Ferrero DV, Buck-Barrington L, et al. Multicenter evaluation of the BDProbeTec ET system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical swabs, and male urethral swabs. J Clin Microbiol. 2001;39:1008–1016. doi: 10.1128/JCM.39.3.1008-1016.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Howell MR, Quinn TC, Brathwaite W, Gaydos CA. Screening women for Chlamydia trachomatis in family planning clinics. The cost-effectiveness of DNA amplification assays. Sex Transm Dis. 1998;25:108–115. doi: 10.1097/00007435-199802000-00008. [DOI] [PubMed] [Google Scholar]
  • 46.Dean D, Ferrero D, McCarthy M. Comparison of performance and cost-effectiveness of direct fluorescent-antibody, ligase chain reaction, and PCR assays for verification of chlamydial enzyme immunoassay results for populations with a low to moderate prevalence of Chlamydia trachomatis infection. J Clin Microbiol. 1998;36:94–99. doi: 10.1128/jcm.36.1.94-99.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.2001 Sexually Transmitted Diseases Laboratory Test Method Survey. Washington, DC: Association of Public Health Laboratories; 2002. pp. 1–19. [Google Scholar]
  • 48.Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines 2002. MMWR Morb Mortal Wkly Rep. 2002;51(RR-6):32–42. [PubMed] [Google Scholar]
  • 49.2001 Drug Topics Red Book. Montvale, NJ: Medical Economics Company; 2001. [Google Scholar]
  • 50.Gift T, Varghese B, Kraut, J, et al. The cost-effectiveness of jail-based STD and HIV prevention programs and their impact on inmate and community health [abstract]. Presented at: National STD Prevention Conference; March 4–7, 2002; San Diego, CA.
  • 51.Martin DH, Mroczkowski TF, Dalu ZA, et al. A controlled trial of a single dose of azithromycin for treatment of chlamydial urethritis and cervicitis. N Engl J Med. 1992;327:921–925. doi: 10.1056/NEJM199209243271304. [DOI] [PubMed] [Google Scholar]
  • 52.Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:54–62. doi: 10.1097/00042560-199709010-00009. [DOI] [PubMed] [Google Scholar]
  • 53.Women Offenders. Washington, DC: Bureau of Justice Statistics; 1999. [Google Scholar]
  • 54.Marrazzo JM, Celum CL, Hillis SD, Fine D, DeLisle S, Handsfield HH. Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women, implications for a national chlamydia control strategy. Sex Transm Dis. 1997;24:131–141. doi: 10.1097/00007435-199703000-00003. [DOI] [PubMed] [Google Scholar]
  • 55.Brocklehurst P. Update on the treatment of sexually transmitted infections in pregnancy-1. Int J STD AIDS. 1999;10:571–580. doi: 10.1258/0956462991914690. [DOI] [PubMed] [Google Scholar]
  • 56.Hammerschlag MR, et al. Chlamydial infections in infants and children. In: Holmes KK, Sparling PF, Mardh P, et al., editors. Sexually Transmitted Diseases. New York: McGraw-Hill; 1999. pp. 1155–1164. [Google Scholar]
  • 57.Ostergaard L. Diagnosis of urogenital Chlamydia trachomatis infection by use of DNA amplification. APMIS. 1999;107(suppl 89):5–36. [PubMed] [Google Scholar]
  • 58.Gutman LT, et al. Gonococcal diseases in infants and children. In: Holmes KK, Sparling PF, Mardh P, et al., editors. Sexually Transmitted Diseases. New York: McGraw-Hill; 1999. pp. 1145–1153. [Google Scholar]
  • 59.Bureau of Labor Statistics. Consumer price index—all urban consumers; 2003. [Database on the Internet]. Available at: http://www.bls.gov/cpihome.htm. Accessed June 16, 2003.
  • 60.Lenderman CJ, Jones M, Hook EW., III Comparison of the Binax Now gonorrhea test with Abbott LCR and culture for the detection of Neisseria gonorrhoeae in men and women [abstract] Int J STD AIDS. 2002;12(suppl 1):98–98. [Google Scholar]
  • 61.Young H, Moyes A, Tideman R, McMillan A. The Binax NOW test for the rapid diagnosis of gonorrhoeae in men [abstract] Int J STD AIDS. 2002;12(suppl 1):98–98. [Google Scholar]
  • 62.Theodore M, Hook EW, III, Mableton S, Whittington WLH, Gaydos CA. Use of Thermo BioStar optical immunoassay (OIA) as a point of care assay for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) in sexually transmitted disease clinics [abstract] Int J STD AIDS. 2002;12(suppl 1):118–118. [Google Scholar]
  • 63.Conklin TJ, Lincoln T, Flanigan TP. A public health model to connect correctional health care with communities. Am J Public Health. 1999;88:1249–1250. [PubMed] [Google Scholar]
  • 64.Skolnick AA. Correctional and community health care collaborations. JAMA. 1998;279:98–99. doi: 10.1001/jama.279.2.98. [DOI] [PubMed] [Google Scholar]
  • 65.Richie BE, Freudenberg N, Page J. Reintegrating women leaving jail into urban communities: a description of a model program. J Urban Health. 2001;78:290–303. doi: 10.1093/jurban/78.2.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Gift TL, Walsh C, Haddix AC, Irwin KL. A cost effectiveness evaluation of testing and treatment of Chlamydia trachomatis infection among asymptomatic women infected with Neisseria gonorrhoeae. Sex Transm Dis. 2002;29:542–551. doi: 10.1097/00007435-200209000-00009. [DOI] [PubMed] [Google Scholar]
  • 67.Kacena KA, Quinn SB, Howell MR, et al. Pooling urine samples for ligase chain reaction screening for genital Chlamydia trachomatis infection in asymptomatic women. J Clin Microbiol. 1998;36:481–485. doi: 10.1128/jcm.36.2.481-485.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Kacena KA, Quinn SB, Hartman SC, Quinn TC, Gaydos CA. Pooling of urine samples for screening for Neisseria gonorrhoeae by ligase chain reaction: accuracy and application. J Clin Microbiol. 1998;36:3624–3628. doi: 10.1128/jcm.36.12.3624-3628.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Peeling RW, Toye B, Jessamine P, Gemmill I. Pooling of urine specimens for PCR testing: a cost saving strategy for Chlamydia trachomatis control programmes. Sex Transm Infect. 1998;74:66–70. doi: 10.1136/sti.74.1.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Krepel J, Patel J, Sproston A, et al. The impact on accuracy and cost of ligase chain reaction testing by pooling urine specimens for the diagnosis of Chlamydia trachomatis infections. Sex Transm Dis. 1999;26:504–507. doi: 10.1097/00007435-199910000-00004. [DOI] [PubMed] [Google Scholar]
  • 71.Morre SA, Meijer CJLM, Munk C, et al. Pooling of urine specimens for detection of asymptomatic Chlamydia trachomatis infections by PCR in a low-prevalence population: cost-saving strategy for epidemiological studies and screening programs. J Clin Microbiol. 2000;38:1679–1680. doi: 10.1128/jcm.38.4.1679-1680.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Centers for Disease Control and Prevention Notice to readers: discontinuation of cefixime tablets—United States. MMWR Morb Mortal Wkly Rep. 2002;51:1052–1052. [PubMed] [Google Scholar]
  • 73.Centers for Disease Control and Prevention Increases in flouroquinolone-resistant Neisseria gonorrhoeae—Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep. 2002;51:1041–1044. [PubMed] [Google Scholar]
  • 74.Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis. 1995;20(suppl 1):S47–S65. doi: 10.1093/clinids/20.supplement_1.s47. [DOI] [PubMed] [Google Scholar]
  • 75.Bala M, Ray K, Kumari S. Alarming increase in ciprofloxacin- and penicillin-resistant Neisseria gonorrhoeae isolates in New Delhi, India. Sex Transm Dis. 2003;30:523–525. doi: 10.1097/00007435-200306000-00010. [DOI] [PubMed] [Google Scholar]
  • 76.Augenbraun M, Bachmann L, Wallace T, Dubouchet L, McCormack W, Hook EW. Compliance with doxycycline therapy in sexually transmitted diseases clinics. Sex Transm Dis. 1998;25:1–4. doi: 10.1097/00007435-199801000-00001. [DOI] [PubMed] [Google Scholar]
  • 77.Handsfield HH, Stamm WE. Treating chlamydial infection: compliance versus cost [editorial] Sex Transm Dis. 1998;25:12–13. doi: 10.1097/00007435-199801000-00003. [DOI] [PubMed] [Google Scholar]
  • 78.Howell MR, Quinn TC, Gaydos CA. Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics: a cost-effectiveness analysis of three strategies. Ann Intern Med. 1998;128:277–284. doi: 10.7326/0003-4819-128-4-199802150-00005. [DOI] [PubMed] [Google Scholar]
  • 79.Mehta SD, Bishai D, Howell MR, Rothman RE, Quinn TC, Zenilman JM. Cost-effectiveness of five strategies for gonorrhea and chlamydia control among female and male emergency department patients. Sex Transm Dis. 2002;29:83–91. doi: 10.1097/00007435-200202000-00004. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES